Alexion Pharmaceuticals Inc. Reports First Quarter 2014 Results

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results and a development pipeline update for the three months ended March 31, 2014. The Company reported net product sales of Soliris® (eculizumab) of $566.6 million, including reimbursement of prior year shipments related to an agreement with the French government of $87.8 million, an increase of 67 percent from the same period in 2013.

Help employers find you! Check out all the jobs and post your resume.